Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque Psoriasis
ARQ-151 potential "Best in Class" topical PDE4 inhibitor Plaque psoriasis affects approximately 8.6 million patients in the U.S. Phase 3...